Skip to main content

Adbry FDA Approval History

Last updated by Judith Stewart, BPharm on Dec 31, 2023.

FDA Approved: Yes (First approved December 27, 2021)
Brand name: Adbry
Generic name: tralokinumab-ldrm
Dosage form: Injection
Company: LEO Pharma Inc.
Treatment for: Atopic Dermatitis

Adbry (tralokinumab-ldrm) is an interleukin-13 antagonist used for the treatment of moderate-to-severe atopic dermatitis.

Development timeline for Adbry

DateArticle
Dec 15, 2023Approval LEO Pharma Inc. Announces U.S. FDA Approval of Adbry (tralokinumab-ldrm) for the Treatment of Moderate-to-Severe Atopic Dermatitis in Pediatric Patients Aged 12-17 Years
Dec 28, 2021Approval FDA Approves Adbry (tralokinumab-ldrm) for Adults with Moderate-to-Severe Atopic Dermatitis
Jul  9, 2020LEO Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of Biologics License Application (BLA) for Tralokinumab for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis
Jun 12, 2020Tralokinumab Achieves Primary and Secondary Endpoints in Three Pivotal Phase 3 Trials in Adult Patients with Moderate-to-Severe Atopic Dermatitis

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.